Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects

2010927 citationsJournal Articlebronze Open Access

Authors

W. P. T. James · University of London

Ian D. Caterson · University of Sydney

Walmir Coutinho · Pontifical Catholic University of Rio de Janeiro

Nick Finer · University College London

Luc F. Van Gaal · Antwerp University Hospital

Aldo P. Maggioni · Associazione Nazionale Medici Cardiologi Ospedalieri

Christian Torp‐Pedersen

Abstract

Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause. (Funded by Abbott; ClinicalTrials.gov number, NCT00234832.)

Topics & Keywords

Pharmacology and Obesity Treatment Blood Pressure and Hypertension Studies Cardiovascular Syncope and Autonomic Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 363, Issue 10, pp. 905-917

DOI: 10.1056/nejmoa1003114

Field-Weighted Citation Impact: 86.12